Dementia Treatment Market Report 2025 (Global Edition)

Global Dementia Treatment Market Report 2025 Market Size Split by Type (Alzheimer’s Dementia, Vascular Dementia, Lewy Body Dementia, Frontotemporal Dementia, Parkinson Disease Dementia, Others), by ...

Dementia Treatment Market Report Description

We have various report editions of Dementia Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape: Dementia Treatment Market

To meet the increasing demands of consumers the industry players are now investing and giving more attention to their research and development of Dementia Treatment so that they sustain and survive in the competition. ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.
 

Top Companies Market Share in Dementia Treatment Industry: (In no particular order of Rank)

• Pfizer Inc.
• Brain Scope
• Lilly
• Biogen
• Viatris Inc.
• Johnson & Johnson
• Abbvie Inc
• Sun Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Otsuka Pharmaceutical Co. Ltd
• Cipla Inc.
• H. Lundbeck A/S
• Apotex Inc.
• F. Hoffmann- La Roche AG
• Teva Pharmaceutical Industries
• Merz Pharma GmbH & Co. KGaA
• Mylan N.V
• Dr. Reddy Laboratories Ltd
• Zydus Cadila
• Allergan plc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Which Region will dominate the Dementia Treatment Market in 2024?

According to Cognitive Research, the North American region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future. High disease prevalence, the existence of important pharmaceutical companies involved in the marketing and research of novel dementia medications, and favorable government initiatives are all key drivers of market expansion. For instance, in June 2023, Health Canada announced the start of the approval procedure for lecanemab in the country. Furthermore, the Alzheimer's Association of Canada reports that the condition affects approximately 747,000 people in the country.
(Source-https://www.eisai.com/news/2023/news202334.html)

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is projected to grow at a CAGR of XX% over the period. This expansion is being fueled by the region's big target population, high unmet clinical requirements, and increasing healthcare infrastructure, all of which offer enormous growth prospects. Countries such as China and India, with large patient populations and high unmet medical requirements, present appealing market opportunities for regional firms.

The current report Scope analyzes Dementia Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Dementia Treatment Market Analysis

According to Cognitive Market Research, the North America Dementia Treatment Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD 33.7 Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031

Europe Dementia Treatment Market Analysis

According to Cognitive Market Research, the Europe Dementia Treatment Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD 33.7 Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031

Asia-Pacific Dementia Treatment Market Analysis

According to Cognitive Market Research, the Asia-Pacific Dementia Treatment Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD 33.7 Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

South America Dementia Treatment Market Analysis

According to Cognitive Market Research, the South America Dementia Treatment Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD 33.7 Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031

Middle East Dementia Treatment Market Analysis

According to Cognitive Market Research, the Middle East and Africa Dementia Treatment Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD 33.7 Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

Dementia Treatment Market Analysis

The Alzheimer's dementia type segment accounts for the largest market share and is expected to rise over the period. According to the Alzheimer's Association 2021 report, the US Food and Drug Administration (FDA) has approved five medications for Alzheimer's treatment: rivastigmine, galantamine, donepezil, memantine, and memantine coupled with donepezil. The study also found that the vast majority of patients who develop Alzheimer's disease are 65 years or older. This is known as late-onset Alzheimer's. Furthermore, in the United States, Alzheimer's dementia affects about 5.3% of persons aged 65 to 74, 13.8% of those aged 75 to 84, and 34.6% of people aged 85 and up. In addition, an estimated 6.2 million Americans aged 65 and older will be living with Alzheimer's dementia in 2021, with a predicted increase to 13.5 million by 2050.
(Source-https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-20048103)

Vascular dementia is the market's fastest-growing sector, defined as cognitive impairment caused by impaired blood flow to the brain. This type of dementia is commonly caused by a stroke or other vascular problems. Pharmaceutical therapies in this section are intended to target the underlying vascular causes and prevent additional cognitive loss. Treatment plans frequently include risk factor management, such as hypertension and diabetes.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Dementia Treatment Industry. Request a Free Sample PDF!

In 2023, cholinesterase inhibitors dominated the market, accounting for XX% of the total. High prescription rates for donepezil, rivastigmine, and galantamine, as well as improved results, are significant drivers of market expansion. Furthermore, the increasing use of transdermal cholinesterase inhibitors, as well as their superior safety and efficacy, are driving market expansion. For instance, Corium, LLC reported data in September 2023 indicating that Adlarity (donepezil transdermal system) demonstrated positive outcomes in terms of skin tolerability and adherence in a placebo-controlled experiment.
(Source-https://www.dermatologytimes.com/view/donepezil-patch-shows-favorable-results-on-skin-irritation-trial)
However, the combination pharmaceuticals market is expected to have the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by the increasing use of combination medication, which has proven to be more effective than monotherapy. Furthermore, significant players are releasing novel combination medications to the marketplace. For instance, in April 2022, NovaMedica developed and registered a combination of donepezil and memantine molecules under the brand name Mioreol in Russia and Europe. The increasing global approval of combination treatments containing cholinesterase inhibitors and NMDA receptor antagonists is propelling expansion in this segment.
(Source-https://novamedica.com/media/our_news/p/12767-novamedica-launches-own-innovative-drug-for-the-treatment-of-alzheimers-disease)

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Dementia Treatment Route of Administration Segment Analysis

The oral method of administration led the market in 2023 with a share of XX% and is expected to maintain its dominance in the coming years. The high market penetration of oral pharmaceuticals such as memantine, donepezil, rivastigmine, galantamine, and others, the large number of pharmaceutical companies supplying these oral drugs, and the increasing approval of oral drugs are the primary reasons driving the segment's expansion. For instance, in May 2023, the US FDA granted additional approval for Rexulti (brexpiprazole) oral tablets to treat dementia-related agitation.
(Source-https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-agitation-symptoms-associated-dementia-due-alzheimers-disease#:~:text=Today%2C%20the%20U.S.%20Food%20and,treatment%20option%20for%20this%20indication.)

The injectable pharmaceuticals segment is expected to expand at the fastest compound annual growth rate (CAGR) from 2024 to 2033. This expansion is being driven by increased research and development initiatives targeted at producing innovative biological therapies, as well as the approval of injectable medications that have demonstrated enhanced efficacy in treating dementia. For Instance, in July 2021, Biogen and Eisai Co., Ltd. got FDA approval for Aduhelm injectable to treat dementia caused by Alzheimer's disease.
(Source-https://www.eisai.com/news/2021/news202141.html)

• Oral
• Transdermal Patch
• Injectable

Dementia Treatment Distribution Channel Segment Analysis

In 2023, hospital pharmacies dominated the market, accounting for XX% of the total. The older population's increasing hospitalization rate due to dementia is driving the segment's rise. According to the Alzheimer's Association Report 2023, there were 518 hospitalizations per 1,000 Medicare beneficiaries aged 65 and older with Alzheimer's or other types of dementia, compared to just 234 hospitalizations per 1,000 Medicare beneficiaries who did not have these disorders.
(Source-https://www.alzsd.org/wp-content/uploads/2023/03/Michelle-Reuwers-Summary-of-the-2022-Alzheimers-Disease-Facts-and-Figures-Report.pdf)

On the other side, the internet category is expected to develop at the fastest compound annual growth rate (CAGR) between 2024 and 2033. This expansion is being driven by factors such as an expanding internet and smartphone user base, the convenience of obtaining drugs through e-commerce platforms, and the increased availability of online pharmacies around the globe. Furthermore, the increased use of telemedicine to manage mental health is projected to fuel growth in this segment in the coming years.

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion